Posted by Michael Wonder on 09 Mar 2016
Call for patient input on a submission from Merck for a subsequent entry biologic
9 March 2016 - CADTH has received notice of a pending submission from Merck for etanercept for use by certain patients with rheumatoid arthritis and ankylosing spondylitis.
For more details, go to: https://www.cadth.ca/etanercept
